Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance
Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance
复制标题
DOI：
10.1093/cid/cix526
复制
发表时间：
2017-10-15
影响因子：
11.8
通讯作者：
Larsen, Joseph
中科院分区：
文献类型：
--
作者：
Ardal, Christine;Rottingen, John-Arne;Larsen, Joseph
需要新的替代市场模式来激励公司投资开发新的抗菌药物。在之前的一份出版物中，跨大西洋抗菌素耐药性工作组（TATFAR）总结了对抗菌药物开发的经济激励达成共识的关键领域。这项工作表明，各方在以下问题上达成了实质性共识：有必要采取推拉混合的激励措施，特别是那些有助于将收入与销量脱钩的激励措施。拉动激励通过增加或确保未来收入来奖励成功的开发。已经提出了几个拉动激励措施，可以大大奖励新的抗菌药物的发展。在由TATFAR代表撰写的第二篇文章中，我们研究了抗菌药物开发的不同拉动激励的优缺点。TATFAR希望这一分析与其他相关分析相结合，将提供可操作的信息，从而影响决策者对这一重要问题的思考。
New alternative market models are needed to incentivize companies to invest in developing new antibacterial drugs. In a previous publication, the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) summarized the key areas of consensus for economic incentives for antibacterial drug development. That work determined that there was substantial agreement on the need for a mixture of push and pull incentives and particularly those that served to delink the revenues from the volumes sold. Pull incentives reward successful development by increasing or ensuring future revenue. Several pull incentives have been proposed that could substantially reward the development of new antibacterial drugs. In this second article authored by representatives of TATFAR, we examine the advantages and disadvantages of different pull incentives for antibacterial drug development. It is TATFAR's hope that this analysis, combined with other related analyses, will provide actionable information that will shape policy makers' thinking on this important issue.